JP5106635B2 - 関節リウマチと関連する抗原 - Google Patents

関節リウマチと関連する抗原 Download PDF

Info

Publication number
JP5106635B2
JP5106635B2 JP2010531449A JP2010531449A JP5106635B2 JP 5106635 B2 JP5106635 B2 JP 5106635B2 JP 2010531449 A JP2010531449 A JP 2010531449A JP 2010531449 A JP2010531449 A JP 2010531449A JP 5106635 B2 JP5106635 B2 JP 5106635B2
Authority
JP
Japan
Prior art keywords
antibody
domain
amino acid
seq
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2010531449A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011502137A (ja
JP2011502137A5 (enExample
Inventor
カスパー，マニュエラ
シュウェイジャー，キャスリン
トラクセル，イブライン
Original Assignee
フィロゲン エスピーエー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by フィロゲン エスピーエー filed Critical フィロゲン エスピーエー
Publication of JP2011502137A publication Critical patent/JP2011502137A/ja
Publication of JP2011502137A5 publication Critical patent/JP2011502137A5/ja
Application granted granted Critical
Publication of JP5106635B2 publication Critical patent/JP5106635B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1018—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2010531449A 2007-10-30 2008-10-27 関節リウマチと関連する抗原 Active JP5106635B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US98360607P 2007-10-30 2007-10-30
US60/983,606 2007-10-30
PCT/EP2008/009070 WO2009056268A1 (en) 2007-10-30 2008-10-27 An antigen associated with rheumatoid arthritis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2012219986A Division JP6154594B2 (ja) 2007-10-30 2012-10-02 関節リウマチと関連する抗原

Publications (3)

Publication Number Publication Date
JP2011502137A JP2011502137A (ja) 2011-01-20
JP2011502137A5 JP2011502137A5 (enExample) 2012-08-30
JP5106635B2 true JP5106635B2 (ja) 2012-12-26

Family

ID=40282320

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2010531449A Active JP5106635B2 (ja) 2007-10-30 2008-10-27 関節リウマチと関連する抗原
JP2012219986A Active JP6154594B2 (ja) 2007-10-30 2012-10-02 関節リウマチと関連する抗原
JP2014210887A Active JP6198703B2 (ja) 2007-10-30 2014-10-15 関節リウマチと関連する抗原

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2012219986A Active JP6154594B2 (ja) 2007-10-30 2012-10-02 関節リウマチと関連する抗原
JP2014210887A Active JP6198703B2 (ja) 2007-10-30 2014-10-15 関節リウマチと関連する抗原

Country Status (18)

Country Link
US (4) US8222377B2 (enExample)
EP (3) EP3281952B1 (enExample)
JP (3) JP5106635B2 (enExample)
KR (3) KR101608544B1 (enExample)
CN (2) CN101918443B (enExample)
AU (1) AU2008317941B2 (enExample)
BR (1) BRPI0818272B8 (enExample)
CA (1) CA2704296C (enExample)
DK (2) DK3281952T3 (enExample)
ES (2) ES2807753T3 (enExample)
HU (2) HUE037036T2 (enExample)
MX (1) MX2010004726A (enExample)
NO (1) NO2209805T3 (enExample)
PL (2) PL2209805T3 (enExample)
PT (2) PT3281952T (enExample)
RU (2) RU2486198C2 (enExample)
SI (2) SI2209805T1 (enExample)
WO (1) WO2009056268A1 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070084556A1 (en) 2005-10-14 2007-04-19 Langseder Neal E Method of applying a label to a squeeze tube
JP5221641B2 (ja) 2007-04-02 2013-06-26 フィロゲン エスピーエー 腫瘍転移の血管新生と関連するフィブロネクチンのｅｄ−ａ抗原
US10202442B2 (en) 2007-07-25 2019-02-12 Philogen S.P.A. Antigen associated with lung cancers and lymphomas
SI2209805T1 (sl) 2007-10-30 2017-11-30 Philogen S.P.A. Antigen, povezan z revmatoidnim artritisom
EP2379116B1 (en) * 2009-01-07 2015-08-26 Philogen S.p.A. Antigens associated with endometriosis
EP2947096B1 (en) 2009-08-05 2018-11-28 Philogen S.p.A. Targeting of bone marrow neovasculature
WO2013014149A1 (en) * 2011-07-27 2013-01-31 Philogen S.P.A. Il-12 immunoconjugate
BR112015002085A2 (pt) * 2012-08-08 2017-12-19 Roche Glycart Ag proteína, polinucleotídeo, vetor, célula hospedeira, método para produzir a proteína, composição farmacêutica, uso da proteína, método de tratamento e invenção
TWI499426B (zh) * 2012-09-27 2015-09-11 Philogen Spa 與發炎性腸病有關之抗原
US9695232B2 (en) 2012-10-03 2017-07-04 Philogen S.P.A. Anti-ED-A immunoconjugates for inflammatory bowel disease
EP3102594A1 (en) * 2014-02-06 2016-12-14 F. Hoffmann-La Roche AG Interleukine 10 immunoconjugates
GB201507908D0 (en) 2015-05-08 2015-06-24 Philogen Spa IL2 and TNF immunoconjugates
CR20180087A (es) 2015-07-16 2018-05-14 Philogen Spa Inmunoconjugados de il22
US20190309060A1 (en) 2016-01-15 2019-10-10 Philogen S.P.A. Intestinal antigens for pharmacodelivery applications
JP2017197558A (ja) * 2017-06-07 2017-11-02 フィロゲン エスピーエー 炎症性腸疾患に関連する抗原
AU2018281871B2 (en) 2017-06-07 2022-07-28 Philogen S.P.A. Vascular endothelial growth factor/anti-fibronectin antibody fusion proteins
WO2020172631A2 (en) 2019-02-21 2020-08-27 Xencor, Inc. Untargeted and targeted il-10 fc-fusion proteins
CN121652287A (zh) * 2019-03-06 2026-03-13 德卡生物科学公司 Il-10变体分子和治疗炎性疾病和肿瘤的方法
WO2020249757A1 (en) 2019-06-14 2020-12-17 Philogen S.P.A Immunoconjugates comprising a single chain diabody and interleukin-15 or interleukin-15 and a sushi domain of interleukin-15 receptor alpha
EP4181957A4 (en) 2020-07-20 2024-08-07 Deka Biosciences, Inc. TWO-CYTOKINE FUSION PROTEIN COMPRISING IL-10
US20230285585A1 (en) 2020-07-22 2023-09-14 Philogen S.P.A. Treatment of pulmonary hypertension
CN113480636B (zh) * 2021-06-23 2023-11-03 烟台科瑞斯生物技术有限责任公司 重组人纤连蛋白及其制备、活性测定和稳定性实验方法
WO2023175077A1 (en) 2022-03-17 2023-09-21 Philogen S.P.A Anti-ed-a antibodies for the treatment of pulmonary hypertension
WO2026003203A1 (en) 2024-06-27 2026-01-02 Philogen S.P.A. Combination of an immunocytokine comprising targeted il2 and a jak inhibitor

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
IT1217724B (it) 1988-05-26 1990-03-30 Ist Naz Ric Sul Cancro Anticorpo monoclonale specifico per una sequenza di fibronettina espressa in cellule trasformate ibridoma secernente tale anticorpo e impiego dell'anticorpo monoclonale per la diagnosi di tumori
US5420012A (en) 1989-05-08 1995-05-30 Locus Genex Oy Method for the detection of reactive conditions
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
GB9206318D0 (en) 1992-03-24 1992-05-06 Cambridge Antibody Tech Binding substances
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
WO1992017604A1 (fr) * 1991-03-26 1992-10-15 Otsuka Pharmaceutical Factory, Inc. Anticorps monoclonal anti-eda
US6492160B1 (en) 1991-05-15 2002-12-10 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US6225447B1 (en) 1991-05-15 2001-05-01 Cambridge Antibody Technology Ltd. Methods for producing members of specific binding pairs
US5858657A (en) 1992-05-15 1999-01-12 Medical Research Council Methods for producing members of specific binding pairs
US5871907A (en) 1991-05-15 1999-02-16 Medical Research Council Methods for producing members of specific binding pairs
US5962255A (en) 1992-03-24 1999-10-05 Cambridge Antibody Technology Limited Methods for producing recombinant vectors
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5872215A (en) 1991-12-02 1999-02-16 Medical Research Council Specific binding members, materials and methods
PT1696031E (pt) 1991-12-02 2010-06-25 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
JP3720353B2 (ja) 1992-12-04 2005-11-24 メディカル リサーチ カウンシル 多価および多重特異性の結合タンパク質、それらの製造および使用
US5644033A (en) 1992-12-22 1997-07-01 Health Research, Inc. Monoclonal antibodies that define a unique antigen of human B cell antigen receptor complex and methods of using same for diagnosis and treatment
WO1994017411A1 (en) 1993-01-27 1994-08-04 Duke University Methods and agents for the diagnosis and treatment of rheumatoid arthritis
US6054312A (en) 1997-08-29 2000-04-25 Selective Genetics, Inc. Receptor-mediated gene delivery using bacteriophage vectors
EP1137941B2 (en) 1998-12-10 2013-09-11 Bristol-Myers Squibb Company Protein scaffolds for antibody mimics and other binding proteins
PT1257297E (pt) 2000-02-24 2006-12-29 Philogen Spa Composições e método para tratamento da angiogénese em lesões patológicas
CA2404919A1 (en) * 2000-04-06 2002-10-01 Kyowa Hakko Kogyo Co. Ltd. Diagnostic and therapeutic agents for rheumatoid arthritis
WO2001083816A2 (en) 2000-05-04 2001-11-08 Philogen S.R.L. Method for detecting tumors
PL364358A1 (en) * 2000-09-07 2004-12-13 Schering Ag Receptor in the edb fibronectin domain (ii)
US6780594B2 (en) 2000-09-25 2004-08-24 Schering Aktiengesellschaft Method for in vitro diagnosis of endometriosis
IT1317108B1 (it) 2000-12-06 2003-05-26 Philogen Srl Processo per la selezione di frammenti anticorporali anti-angiogenesi,frammenti anticorpali anti-angiogenesi cosi' ottenuti e loro uso.
US20020187100A1 (en) 2000-12-21 2002-12-12 David Rizzieri Anti-tenascin monoclonal antibody therapy for lymphoma
EP1224943A1 (en) 2001-01-19 2002-07-24 Crucell Holland B.V. Fibronectin as a tumor marker detected by phage antibodies
GB0209896D0 (en) * 2002-04-30 2002-06-05 Molmed Spa Conjugate
AU2003238284A1 (en) 2002-06-21 2004-01-06 Duke University Anti-tenascin antibody fragments and minibodies for treatment of lymphoma
EP1572131B1 (en) * 2002-10-08 2016-07-06 Immunomedics, Inc. Antibody therapy
JP4959136B2 (ja) 2002-12-13 2012-06-20 イミューノメディクス、インコーポレイテッド 細胞内で開裂可能な結合を有する免疫接合体
US20040202666A1 (en) 2003-01-24 2004-10-14 Immunomedics, Inc. Anti-cancer anthracycline drug-antibody conjugates
US7560095B2 (en) 2003-04-22 2009-07-14 A & G Pharmaceutical, Inc. Cancer specific monoclonal antibodies
WO2005009366A2 (en) 2003-07-24 2005-02-03 Cornell Research Foundation, Inc. Restoring vascular function
CA2533878A1 (en) 2003-07-29 2005-09-22 Immunomedics, Inc. Fluorinated carbohydrate conjugates
AU2005203962C1 (en) 2004-01-05 2012-11-08 Antisoma Research Limited Interleukin-12 targeted to oncofoetal fibronectin
US20060024722A1 (en) 2004-07-30 2006-02-02 Mark Fischer-Colbrie Samples for detection of oncofetal fibronectin and uses thereof
US7785591B2 (en) * 2004-10-14 2010-08-31 Morphosys Ag Identification and characterization of function-blocking anti-ED-B-fibronectin antibodies
PL1817345T3 (pl) 2004-11-09 2009-10-30 Philogen Spa Przeciwciała przeciwko tenascynie-C
CA2593964A1 (en) * 2004-12-23 2006-06-29 Molmed Spa Conjugation product
KR101281208B1 (ko) * 2005-05-11 2013-07-26 필로겐 에스.피.에이. 피브로넥틴 ｅｄ-ｂ에 대한 항체 ｌ１９ 및 인터루킨１２의 융합 단백질
JP2009505947A (ja) 2005-06-23 2009-02-12 エモリー・ユニバーシティ 画像化剤
EP2015775B1 (en) 2006-05-03 2011-06-01 Bayer Schering Pharma Aktiengesellschaft Combination of an anti edb fibronectin domain antibody l19-sip and an anti-egfr antibody
KR20090008467A (ko) * 2006-05-08 2009-01-21 필로겐 에스.피.에이. 치료용의 항체­표적 사이토카인
JP5221641B2 (ja) 2007-04-02 2013-06-26 フィロゲン エスピーエー 腫瘍転移の血管新生と関連するフィブロネクチンのｅｄ−ａ抗原
US10202442B2 (en) 2007-07-25 2019-02-12 Philogen S.P.A. Antigen associated with lung cancers and lymphomas
CN101754978B (zh) 2007-07-25 2013-06-05 菲洛根股份公司 一种与肺癌和淋巴瘤相关的抗原
SI2209805T1 (sl) 2007-10-30 2017-11-30 Philogen S.P.A. Antigen, povezan z revmatoidnim artritisom
US20110318302A1 (en) 2009-01-07 2011-12-29 Kathrin Schwager Cancer Treatment
EP2379116B1 (en) 2009-01-07 2015-08-26 Philogen S.p.A. Antigens associated with endometriosis
WO2012041451A1 (en) 2010-09-29 2012-04-05 Philogen S.P.A. Thiazolidine linker for the conjugation of drugs to antibodies
WO2013014149A1 (en) 2011-07-27 2013-01-31 Philogen S.P.A. Il-12 immunoconjugate
US9695232B2 (en) 2012-10-03 2017-07-04 Philogen S.P.A. Anti-ED-A immunoconjugates for inflammatory bowel disease
WO2014174105A1 (en) 2013-04-25 2014-10-30 Philochem Ag Antibody-drug conjugates
US20160200789A1 (en) 2013-04-26 2016-07-14 Philogen S.P.A. Il4 conjugated to antibodies against extracellular matrix components
US9209965B2 (en) 2014-01-14 2015-12-08 Microsemi Semiconductor Ulc Network interface with clock recovery module on line card

Also Published As

Publication number Publication date
HUE037036T2 (hu) 2018-08-28
US9556257B2 (en) 2017-01-31
EP2209805B1 (en) 2017-09-06
DK3281952T3 (da) 2020-08-03
EP3783019A1 (en) 2021-02-24
HUE050038T2 (hu) 2020-11-30
AU2008317941B2 (en) 2015-01-22
CN103396483B (zh) 2016-11-23
MX2010004726A (es) 2010-05-20
BRPI0818272A2 (pt) 2015-04-14
EP3281952A1 (en) 2018-02-14
CN103396483A (zh) 2013-11-20
RU2013115891A (ru) 2014-10-20
SI2209805T1 (sl) 2017-11-30
DK2209805T3 (en) 2017-10-16
PL2209805T3 (pl) 2018-01-31
KR20160039305A (ko) 2016-04-08
RU2010121874A (ru) 2011-12-10
ES2646228T3 (es) 2017-12-12
US10385121B2 (en) 2019-08-20
CN101918443A (zh) 2010-12-15
BRPI0818272B8 (pt) 2021-05-25
RU2486198C2 (ru) 2013-06-27
CN101918443B (zh) 2013-07-17
KR20180027640A (ko) 2018-03-14
PT3281952T (pt) 2020-07-23
PL3281952T3 (pl) 2020-11-16
JP2015091799A (ja) 2015-05-14
RU2649368C2 (ru) 2018-04-02
KR101608544B1 (ko) 2016-04-01
JP2011502137A (ja) 2011-01-20
KR20100101587A (ko) 2010-09-17
US20190352384A1 (en) 2019-11-21
NO2209805T3 (enExample) 2018-02-03
CA2704296A1 (en) 2009-05-07
ES2807753T3 (es) 2021-02-24
JP6198703B2 (ja) 2017-09-20
WO2009056268A1 (en) 2009-05-07
BRPI0818272B1 (pt) 2021-01-12
EP2209805A1 (en) 2010-07-28
PT2209805T (pt) 2017-11-14
CA2704296C (en) 2017-08-22
EP3281952B1 (en) 2020-06-24
US8222377B2 (en) 2012-07-17
US20100260707A1 (en) 2010-10-14
SI3281952T1 (sl) 2020-09-30
KR102002739B1 (ko) 2019-07-23
AU2008317941A1 (en) 2009-05-07
JP2013040183A (ja) 2013-02-28
JP6154594B2 (ja) 2017-06-28
US20170298122A1 (en) 2017-10-19
US20120244114A1 (en) 2012-09-27
KR101836968B1 (ko) 2018-03-12

Similar Documents

Publication Publication Date Title
JP6198703B2 (ja) 関節リウマチと関連する抗原
AU2008234615B2 (en) The ED-A antigen of fibrinogen is associated with the neovasculature of tumour metastases
JP5705893B2 (ja) 腫瘍転移の新生血管と関連するフィブリノーゲンのｅｄ−ａ抗原
AU2014274545B2 (en) An antigen associated with rheumatoid arthritis
AU2013273761B2 (en) The ed-a antigen of fibrinogen is associated with the neovasculature of tumour metastases
HK1191353B (en) An antigen associated with rheumatoid arthritis
HK1191353A (en) An antigen associated with rheumatoid arthritis

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20101007

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111021

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20111021

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120713

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20120713

TRDD Decision of grant or rejection written
A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20120827

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20120904

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20121002

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

Ref document number: 5106635

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20151012

Year of fee payment: 3

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250